Want to see CTXR full AI Analyst Report?
Citius Pharmaceuticals (CTXR) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 14, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1The conversion of loan principal into shares of Citius Oncology's common stock and the exercise of Lender Warrants could result in significant dilution to its existing stockholders and may adversely affect the market price of its common stock.
Under the terms of the Loan Agreement, the Lenders have the right to convert up to $4.0 million of outstanding principal into shares of Citius Oncology's common stock at a $1.08 per share conversion price. In addition, Citius Oncology has issued warrants to the Lenders equal to 10% of the portion of the loans actually funded that are exercisable at $0.90 per share. The conversion of loan principal and/or the exercise of these warrants would result in the issuance of additional shares of its common stock and would dilute the ownership interest of its existing stockholders, including Citius Pharma. Such anticipated dilution could depress the market price of its common stock, even before any actual conversion or exercise occurs. Furthermore, the Lenders may sell any shares acquired upon conversion or exercise into the market, which could create downward pressure on its stock price. Any or all of these factors could materially adversely affect the market price of its common stock and the value of an investment in its securities, including the shares held by Citius Pharma.
- Debt & Financing - Risk 2The Loan Agreement is secured by a lien on substantially all of Citius Oncology's assets, including its intellectual property, and the Lenders could foreclose on such assets upon an event of default.
Citius Oncology's obligations under the Loan Agreement are secured by a first-priority lien on substantially all of its assets, including its intellectual property, accounts receivable, inventory, equipment, and general intangibles. If an event of default occurs and is not cured within any applicable cure period, the Lenders would have the right to foreclose on the collateral securing Citius Oncology's obligations. The foreclosure on, or loss of, substantially all of Citius Oncology's assets, including its intellectual property, could result in a complete loss of its ability to operate its business and would likely render it unable to continue as a going concern. Citius Oncology's intellectual property, including patents, trademarks, trade secrets, and proprietary technology, constitutes a critical component of its competitive position and revenue-generating capabilities. The loss of such assets to the Lenders in a foreclosure action would have a material adverse effect on its business and could result in a total loss of its stockholder value, which would directly impact Citius Pharma.
- Debt & Financing - Risk 3Additional funding tranches under the Loan Agreement are conditioned upon the achievement of specified milestones, and there can be no assurance that such milestones will be achieved.
The availability of Tranche 2 and Tranche 3 under the Loan Agreement is conditioned upon Citius Oncology's achievement of specified net revenue and liquidity milestones. If it fails to achieve the required milestones within the applicable time periods, Tranche 2 and/or Tranche 3 will not become available to it, and Citius Oncology will not have access to the additional committed capital contemplated by the Loan Agreement. Citius Oncology's failure to access these additional tranches could significantly impair its ability to fund ongoing operations, pursue growth initiatives, or meet its working capital requirements. In such event, Citius Oncology may be required to seek alternative sources of financing, which may not be available on terms acceptable to it, or at all, or Citius Oncology may be required to curtail its operations or delay or abandon planned expenditures. Any of these outcomes could have a material adverse effect on its business, financial condition, results of operations, and prospects, which would directly impact Citius Pharma.
- Debt & Financing - Risk 4Our majority-owned subsidiary, Citius Oncology, has substantial indebtedness and debt service obligations, which could adversely affect our financial condition.
Citius Oncology has incurred significant indebtedness under the Loan Agreement, which features a tiered tranche structure with a floating interest rate subject to a floor of 12.75% per annum. During the interest-only period, Citius Oncology will not reduce the outstanding principal balance of the loan, and upon expiration of such period, it will be required to make amortizing payments of principal and interest. In addition, Citius Oncology is obligated to make a final payment of $1,062,500 at maturity, which creates a balloon-type obligation that Citius Oncology may be unable to satisfy from available cash flows or other sources. There can be no assurance that its business will generate sufficient cash flow from operations or that future borrowings or other sources of capital will be available to it in an amount sufficient to enable it to pay its indebtedness or to fund its other liquidity needs. If Citius Oncology is unable to generate sufficient cash flow to service its debt and meet its other obligations, it may need to refinance or restructure its debt, sell assets, reduce or delay capital expenditures, or seek additional equity capital, any of which could have a material adverse effect on its business, financial condition, and results of operations which would directly impact Citius Pharma.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 59
- Share Price & Shareholder Rights - Risk 1Our Certificate of Incorporation allows for our Board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of the common stock.
Our Board has the authority to issue up to 10,000,000 shares of preferred stock and to fix and determine the relative rights and preferences of any such preferred stock without further stockholder approval. As a result, our Board could authorize the issuance of one or more series of preferred stock that would grant preferential rights to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the preferred shares, together with a premium, prior to the redemption of the common stock. In addition, our Board could authorize the issuance of a series of preferred stock that has greater voting power than the common stock or that is convertible into our common stock, which could decrease the relative voting power of the common stock or result in dilution to our existing stockholders. For example, in April 2025, our Board authorized the issuance of Series A preferred stock. Each share of Series A preferred stock carried 1,000,000,000 votes and voted together with the outstanding shares of our common stock as a single class, exclusively with respect to a proposed increase in the authorized shares allowed under our Amended and Restated Articles of Incorporation and were not entitled to vote on any other matter. The Series A preferred stock had no other voting rights, including in respect of any other proposal to stockholders, except as otherwise mandated by applicable law. The Series A preferred stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series A preferred stock had no rights with respect to any distribution of assets of the Company and was not entitled to receive dividends of any kind. By its terms, the Series A preferred stock was redeemed and retired on June 9, 2025.
- Share Price & Shareholder Rights - Risk 2You may experience dilution of your ownership interests because of the future issuance of additional shares of our common stock or securities convertible into common stock.
For the foreseeable future until LYMPHIR generates significant revenue, if at all, we will need to raise capital to finance our operations, including possible acquisitions or strategic transactions. To do so we might be required to issue equity securities, resulting in the dilution of the ownership interests of our present stockholders. We are currently authorized to issue an aggregate of 250,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of September 30, 2025, there were 18,067,744 shares of common stock outstanding, 14,479,372 shares underlying warrants with a weighted average exercise price of $7.41 per share and 839,510 shares underlying options with a weighted average exercise price of $30.09 per share. We may also issue additional shares of common stock or other securities that are convertible into or exercisable for common stock in connection with hiring or retaining employees, or for other business purposes. The future issuance of any such additional shares of common stock or common stock equivalents may create downward pressure on the trading price of our common stock.
- Share Price & Shareholder Rights - Risk 3The market price of our common stock is highly volatile, and you may lose some or all of your investment.
The market price of our common stock has fluctuated significantly due to a number of factors, some of which are beyond our control, including those factors discussed in this "Risk Factors" and "Risk Factor Summary" section of this report and many others, such as: - the Company's cash resources available to successfully commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services;- the Company's ability to meet its contractual obligations;- the ability of the Company to maintain compliance with the Nasdaq continued listing requirements;- the Company's ability to commercialize its product candidates, if approved and Citius Oncology's ability to successfully commercialize LYMPHIR;- the level of success and the cost of Company's marketing efforts for LYMPHIR and its other product candidates, if approved; - the Company's dependence on third parties - unanticipated serious safety concerns related to the use of its product candidates;- announcements regarding results of any pre-clinical or clinical trials relating to Company's product candidates;- adverse regulatory decisions;- changes in laws or regulations applicable to any product candidates, including but not limited to clinical trial requirements for approvals;- future issuances of debt or equity securities;- actual or anticipated fluctuations in the Company's financial condition and operating results, including fluctuations in our quarterly and annual results;- the Company's inability to establish additional partnerships, the termination of license agreements by our existing partners or announcements by our partners regarding therapeutic candidates competitive with ours;- the introduction of new technologies or enhancements to existing technology by the Company or others in the industry;- the recruitment or departure of key scientific or management personnel;- announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by the Company or our competitors;- the Company's failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;- publication of research reports about the Company or our industry, or antibody discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;- changes in the market valuations of similar companies;- overall performance of the equity markets;- announcements or actions taken by Citius Oncology, as a majority-owned subsidiary of the Company;- the planned distribution of shares common stock of Citius Oncology by Citius Pharma;- sales of shares of common stock by Citius Pharma;- trading volume of the Company's common stock;- legal disputes or other developments relating to proprietary rights, including patents, litigation matters and Company's ability to obtain and maintain patent protection of its product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation;- significant lawsuits, including patent or stockholder litigation;- the impact of any natural disasters or public health emergencies;- general economic, industry and market conditions other events or factors, many of which are beyond the Company's control; and - changes in accounting standards, policies, guidelines, interpretations or principles. In addition, in the past, stockholders have initiated Company action lawsuits against biotechnology and biopharmaceutical companies following periods of volatility in the market prices of these companies' stock. Such litigation, if instituted against us, could cause the Company to incur substantial costs and divert our management's attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.
- Share Price & Shareholder Rights - Risk 4Our failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of our common stock.
Citius Pharma common stock is currently listed on The Nasdaq Capital Market. In order to maintain this listing, we must satisfy minimum financial and other requirements. On September 12, 2023, Citius Pharma received a notification letter from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of our common stock on the Nasdaq Capital Market closed below $1.00 per share for 30 consecutive business days (the "Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), a company has a compliance period of 180 calendar days to regain compliance with the Bid Price Rule and may be eligible for a second 180 calendar day extension period for compliance. As the Company did not regain compliance with the Bid Price Rule within the compliance periods, the Company received a delisting determination letter on September 10, 2024. Accordingly, the Company timely requested a hearing before a Nasdaq Hearing Panel ("Panel"). The hearing request automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. On November 6, 2024, the Company received notification that the Panel, which determined that the Company must be in compliance with the Bid Price Rule by December 3, 2024. On December 18, 2024, following the execution of the Company's reverse stock split, the Company received notification from Nasdaq that it had regained compliance with the Bid Price Rule. On May 29, 2025, the Company received a second determination letter from Nasdaq notifying the Company that, based upon the closing bid price of the Company's common stock for the prior 33 consecutive business days, the Company was not in compliance with the Bid Price Rule and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period due to the fact that the Company had effected a reverse stock split during the prior one-year period. The Company timely requested an appeal of Nasdaq's determination, which stayed the suspension and delisting of the Company's common stock pending a the Panel's decision. Prior to the hearing, the Company received written notice of compliance from Nasdaq that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock had been at $1.00 per share or greater, and accordingly, the Company regained compliance with the Bid Price Rule. Nasdaq informed the Company in the compliance notice that it considered this matter closed. While Citius Pharma intends to maintain compliance in the future, and thus maintain our listing, there can be no assurance that we will be successful and continue to meet all applicable Nasdaq Capital Market requirements in the future. If Citius Pharma's common stock were to be removed from listing with Nasdaq, it may be subject to the so-called "penny stock" rules. The SEC has adopted regulations that define a "penny stock" to be any equity security that has a market price per share of less than $5.00, subject to certain exceptions, such as any securities listed on a national securities exchange, which is the exception on which we currently rely. For any transaction involving a "penny stock," unless exempt, the rules impose additional sales practice requirements on broker-dealers, subject to certain exceptions. If our common stock were delisted and determined to be a "penny stock," a broker-dealer may find it more difficult to trade our common stock and an investor may find it more difficult to acquire or dispose of our common stock on the secondary market. If Citius Pharma's common stock is delisted and there is no longer an active trading market for our shares, it may, among other things: - cause stockholders difficulty in selling Citius Pharma's shares without depressing the market price for the shares or selling the shares at all; - substantially impair the ability to raise additional funds; - result in a loss of institutional investor interest and fewer financing opportunities; and/or - result in potential breaches of representations or covenants of agreements pursuant to which Citius Pharma made representations or covenants relating to compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of management's time and attention and could have a material adverse effect on the financial condition, business and results of operations. A delisting would also reduce the value of Citius Pharma's equity compensation plans, which could negatively impact the ability to retain employees.
- Share Price & Shareholder Rights - Risk 5A planned distribution by Citius Pharma to its stockholders of shares of Citius Oncology could result in significant tax liability to Citius Pharma and our stockholders.
A planned distribution of Citius Oncology shares to our stockholders would not qualify for non-recognition of gain and loss, and therefore, our stockholders could be subject to tax. Each U.S. holder who received Citius Oncology stock in a distribution would generally be treated as receiving a distribution in an amount equal to the fair market value of Citius Oncology common stock received, which would generally result in (i) a taxable dividend to the stockholder to the extent that stockholder's pro rata share of Citius Pharma's current or accumulated earnings and profits; (ii) a reduction in the stockholder's basis (but not below zero) in Citius Pharma's common stock to the extent the amount received exceeds the stockholder's shares of Citius Pharma's earnings and profits; and (iii) a taxable gain from the exchange of Citius Pharma's stock to the extent the amount received exceeds the sum of the stockholder's share of Citius Pharma's earnings and profits and the stockholder's basis in its Citius Pharma stock. Citius Pharma will also recognize a taxable gain in an amount up to the fair market value of any distributed Citius Oncology shares in excess of the taxable basis in such distributed shares.
- Share Price & Shareholder Rights - Risk 6AddedThe conversion of loan principal into shares of Citius Oncology's common stock and the exercise of Lender Warrants could result in significant dilution to its existing stockholders and may adversely affect the market price of its common stock.
Under the terms of the Loan Agreement, the Lenders have the right to convert up to $4.0 million of outstanding principal into shares of Citius Oncology's common stock at a $1.08 per share conversion price. In addition, Citius Oncology has issued warrants to the Lenders equal to 10% of the portion of the loans actually funded that are exercisable at $0.90 per share. The conversion of loan principal and/or the exercise of these warrants would result in the issuance of additional shares of its common stock and would dilute the ownership interest of its existing stockholders, including Citius Pharma. Such anticipated dilution could depress the market price of its common stock, even before any actual conversion or exercise occurs. Furthermore, the Lenders may sell any shares acquired upon conversion or exercise into the market, which could create downward pressure on its stock price. Any or all of these factors could materially adversely affect the market price of its common stock and the value of an investment in its securities, including the shares held by Citius Pharma.
- Share Price & Shareholder Rights - Risk 7Provisions in our Amended and Restated Articles of Incorporation, as amended, and under Nevada law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
Provisions of our articles of incorporation and bylaws may delay or discourage transactions involving an actual or potential change of control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include: - the authorization of 10,000,000 shares of "blank check" preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;- limiting the removal of directors by the stockholders;- allowing for the creation of a staggered Board of Directors;- eliminating the ability of stockholders to call a special meeting of stockholders; and - establishing advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted upon at stockholder meetings. Additionally, Nevada's "combinations with interested stockholders" statutes prohibit certain business "combinations" between certain Nevada corporations and any person deemed to be an "interested stockholder" for two years after such person first becomes an "interested stockholder" unless (i) the corporation's Board of Directors approves the combination (or the transaction by which such person becomes an "interested stockholder") in advance, or (ii) the combination is approved by the Board of Directors and 60% of the corporation's voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval, certain restrictions may apply even after such two-year period. For purposes of these statutes, an "interested stockholder" is any person who is (x) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding shares of the corporation. The definition of the term "combination" is sufficiently broad to cover most significant transactions between the corporation and an "interested stockholder". Subject to certain timing requirements set forth in the statutes, a corporation may elect not to be governed by these statutes. We have not included any such provision in our articles of incorporation. We are not currently subject to Nevada's "acquisition of controlling interest" statutes that contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. If these laws were to apply to us, they might further discourage companies or persons interested in acquiring a significant interest in or control of the Company, regardless of whether such acquisition may be in the interest of our stockholders. The effect of these statutes may be to potentially discourage parties interested in taking control of the Company from doing so if it cannot obtain the approval of our Board of Directors.
- Share Price & Shareholder Rights - Risk 8Conflicts of interest may arise from our relationship with Citius Oncology and NoveCite.
As of December 17, 2025, we beneficially owned approximately 77.9% (excluding pre-funded warrants to purchase up to 15,229,358 shares of Citius Oncology common stock in a transaction that closed on December 10, 2025) of the voting power of Citius Oncology (Nasdaq: CTOR) and 75% of the voting power of NoveCite's outstanding common stock and Novellus owns the other 25% of NoveCite. As a result of our partial ownership, our relationship with each of Citius Oncology and NoveCite could give rise to certain conflicts of interest that could have an impact on our, Citius Oncology's and NoveCite's respective research and development programs, business opportunities, and operations generally. - Even though we utilize different technologies than Citius Oncology or NoveCite, we could find ourselves in competition with either for research scientists, financing and other resources, licensing, manufacturing, and distribution arrangements. - Each of Citius Oncology and NoveCite will engage for its own business in research and product development programs, investments, and business ventures, and we will not be entitled to participate or to receive an interest in those programs, investments, or business ventures other than to the extent as a stockholder in the subsidiary. Citius Oncology and NoveCite will not be obligated to present any particular research and development, investment, or business opportunity to us, even if the opportunity would be within the scope of our research and development plans or programs, business objectives, or investment policies. These opportunities may include, for example, opportunities to acquire businesses or assets, including but not limited to patents and other intellectual property that could be used by us or by Citius Oncology or NoveCite. - Each conflict of interest will be resolved by our respective boards of directors in keeping with their fiduciary duties and such policies as they may implement from time to time. - There is overlap among our board of directors, senior management and research staffs and that of Citius Oncology and NoveCite. All of our directors also serve as directors of Citius Oncology. Two of our directors, Leonard Mazur and Myron Holubiak, also serve as directors of NoveCite. In addition, Myron Holubiak serves as Chief Executive Officer and Jaime Bartushak serves as Chief Financial Officer of each of Citius Pharma, Citius Oncology and NoveCite. These overlapping positions could interfere with the duties owed by such individuals to Citius Pharma.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.